The other panelists with Dr Harry include: Jan Gheuens, MD, PhD (moderator), Senior Program Officer, Global Health Technologies, Bill & Melinda Gates Foundation; Gary M. Cohen, President, BD Medical, BD; Jean-Francois de Lavison, President, European Diagnostic Manufacturers Association; Lawrence A. Siebert, President and CEO, Chembio Diagnostics Inc., and Karen Hedine, President and CEO, Micronics.
Dr Harry said rapid and accurate diagnosis is critical to arrest transmission and to treat TB patients effectively and responsibly. "The primary need is for simple confirmatory and screening tests to distinguish active TB from other conditions with similar symptoms. The PXL test aims to allow direct detection of active TB in sputum and/or blood in a cost effective point of care format for rapid diagnosis," Dr Harry said.
About Proteome Systems
Proteome Systems Limited [ASX: PXL] is an Australian based diagnostics company that has extensive expertise in discovering biomarkers of disease and in diagnostic test development. Its focus is on clinical, nutritional, agricultural and environmental applications where there are large global markets and an unmet need for diagnostics.
Proteome Systems offers commercial partners a clear marketing advantage through its expertise in the development of novel, point-of-need diagnostic tests based on its proprietary test platform, DiagnostIQ(TM). It has the capability to work across the entire spectrum of diagnostic test development -- from identification and isolation of biomarkers, through point-of-need test design, clinical development or field testing to final product.
A collaboration and licensing deal has been entered into with Becton
Dickinson to exploit PXL's biomarkers for the development of new TB
diagnostic products. The Company also has a long standing working
relationship with Bayer CropScience for the manufacture and
|SOURCE Proteome Systems Ltd.|
Copyright©2008 PR Newswire.
All rights reserved